Am­i­cus shares slammed as lead PhI­II drug fails a key head-to-head test for Pompe dis­ease — but the CEO still projects an FDA OK and bright fu­ture

Am­i­cus stock got ham­mered Thurs­day af­ter­noon af­ter the biotech put out word that the crown jew­el in the pipeline just failed the pri­ma­ry end­point in a head-to-head study with the stan­dard of care for Pompe dis­ease.

CEO John Crow­ley, though, has a long track record at spot­light­ing the pos­i­tive, which was on full dis­play in its state­ment on the failed study. Re­searchers for the com­pa­ny high­light­ed some mar­gin­al­ly pos­i­tive sec­ondary da­ta with an im­prove­ment in res­pi­ra­to­ry func­tion from a post hoc analy­sis that they plan to roll ahead to the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER